Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges.
about
Oncological Impact of M-Tor Inhibitor Immunosuppressive Therapy after Liver Transplantation for Hepatocellular Carcinoma: Review of the LiteratureProfile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to dateTargeting Hepatocellular Carcinoma: What did we Discover so Far?Diosmetin triggers cell apoptosis by activation of the p53/Bcl-2 pathway and inactivation of the Notch3/NF-κB pathway in HepG2 cellsA Hybrid Chalcone Combining the Trimethoxyphenyl and Isatinyl Groups Targets Multiple Oncogenic Proteins and Pathways in Hepatocellular Carcinoma CellsShort-term and long-term efficacy of 7 targeted therapies for the treatment of advanced hepatocellular carcinoma: a network meta-analysis: Efficacy of 7 targeted therapies for AHCC.Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma.0404 inhibits hepatocellular carcinoma through a p53/miR-34a/SIRT1 positive feedback loopMetallothionein 1H (MT1H) functions as a tumor suppressor in hepatocellular carcinoma through regulating Wnt/β-catenin signaling pathway.Asialoglycoprotein receptor-magnetic dual targeting nanoparticles for delivery of RASSF1A to hepatocellular carcinoma.Everolimus exhibits anti-tumorigenic activity in obesity-induced ovarian cancer.Knockdown of the differentially expressed gene TNFRSF12A inhibits hepatocellular carcinoma cell proliferation and migration in vitro.Hepatoma-Derived Growth Factor: Its Possible Involvement in the Progression of Hepatocellular Carcinoma.The biology of Hepatocellular carcinoma: implications for genomic and immune therapies.Mus81 knockdown improves chemosensitivity of hepatocellular carcinoma cells by inducing S-phase arrest and promoting apoptosis through CHK1 pathwaymiR-125a inhibits the migration and invasion of liver cancer cells via suppression of the PI3K/AKT/mTOR signaling pathway.Integrating subpathway analysis to identify candidate agents for hepatocellular carcinoma.Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies.Specific expression of proton-coupled oligopeptide transporter 1 in primary hepatocarcinoma-a novel strategy for tumor-targeted therapy.Chemotherapy for Hepatocellular Carcinoma: Current Evidence and Future PerspectivesCombination treatment of ergosterol followed by amphotericin B induces necrotic cell death in human hepatocellular carcinoma cells.Synergistic effect of farnesyl transferase inhibitor lonafarnib combined with chemotherapeutic agents against the growth of hepatocellular carcinoma cells.Female GADD34 mice develop age-related inflammation and hepatocellular carcinoma.Multi-omics integration reveals the landscape of pro-metastasis metabolism in hepatocellular carcinoma.Filomicelles deliver a chemo-differentiation combination of Paclitaxel and Retinoic Acid that durably represses carcinomas in liver to prolong survival.Sorafenib response in hepatocellular carcinoma: MicroRNAs as tuning forks.Facile Fabrication of Reduction-Responsive Supramolecular Nanoassemblies for Co-delivery of Doxorubicin and Sorafenib toward Hepatoma Cells.Current and Future Treatment of Hepatocellular Carcinoma: An Updated Comprehensive Review.Three Dimensional Mixed-Cell Spheroids Mimic Stroma-Mediated Chemoresistance and Invasive Migration in hepatocellular carcinoma.CD13 Inhibition Enhances Cytotoxic Effect of Chemotherapy Agents
P2860
Q28067445-D5543F2F-1AC2-46B1-B833-569C5A8BA891Q28071589-6BC53274-5B30-4349-A85E-3DB3DC9C9150Q28077283-620BC7DC-73F3-4088-9710-55145B7D9127Q28468617-DB1BAD8C-0F3C-454A-BDD8-532465B6C3C2Q28553513-BEDACFB6-F970-4B5C-B3EC-96BFC4D94F7CQ30240170-7A5B71C1-1F75-4ABC-8095-D4DAD8CA7A9CQ33635033-EB0925F7-BCDD-4A90-8935-1CB491881425Q33861041-2474D82D-FEAE-4CD7-8A4E-288E0125D405Q36292211-211C7C22-88ED-419E-9159-60E3FE8A34D3Q36621264-EC3B100E-54CF-43B1-921D-0A5F6C101DDCQ37190310-9EFC5FAD-6CEA-4643-822D-F3FF71DBB8BAQ37722092-1A68E891-444A-48B3-AC0C-099CBAF30942Q38535178-485A5652-E3F1-436B-A8D9-72C85FBF4AD8Q38635474-74293A80-1F29-45E6-AE1C-3313B3106073Q38808165-D227141D-83C0-4E2D-BE1B-B42939671336Q38815508-956D9D5F-8721-42E9-85D1-37433BA1CC8EQ38944703-9DBBAA31-8A3B-483E-BEEF-83038733F14CQ39458547-8972CA42-DA1B-4895-BD85-DC69F82C9000Q41388290-6EC2BE8D-A5A7-4D47-AD2D-EF4CE9752815Q41706847-F6EE932A-6379-45E5-A242-96C72ACFF503Q42700746-FD5A950E-8F7E-4412-B122-3212F7C1572CQ47094177-4620212E-399C-480E-B3F2-AD9D2B005277Q47723717-28008C75-C4B1-406B-B63D-E26EDEAB7965Q49682532-D3305030-24AC-42E6-AC4A-DA897AF9C4A4Q49927417-E81EDAE5-58B0-448C-9677-4EE566D5AD6AQ50063114-7B7049D3-B5A7-4123-91B6-366DCF8979FBQ50318923-F9E2DAAB-638F-4EF9-9CED-D8D3849C2A4EQ55268879-4F3210D5-D466-4D43-B29F-263550F00C7BQ55500782-79CE65C5-B17A-4610-A75F-CECBB714B41CQ58746251-A7AC426B-7205-4F48-A0E3-F325FCFB7BD6
P2860
Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges.
description
2015 nî lūn-bûn
@nan
2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Chemotherapy and target therap ...... : New advances and challenges.
@ast
Chemotherapy and target therap ...... : New advances and challenges.
@en
type
label
Chemotherapy and target therap ...... : New advances and challenges.
@ast
Chemotherapy and target therap ...... : New advances and challenges.
@en
prefLabel
Chemotherapy and target therap ...... : New advances and challenges.
@ast
Chemotherapy and target therap ...... : New advances and challenges.
@en
P2093
P2860
P356
P1476
Chemotherapy and target therap ...... : New advances and challenges.
@en
P2093
P2860
P304
P356
10.4254/WJH.V7.I5.787
P577
2015-04-01T00:00:00Z